CeriBell, Inc. Q4 2025 Earnings Call Summary

Positioned the platform to address the 'acute brain failure' of delirium, targeting a $1 billion greenfield market where no other FDA-cleared monitoring device exists.Maintained high gross margins of 88% for the full year through manufacturing efficiencies and a strategic transition to a Vietnam-based production line.Leveraged FedRAMP High authorization to unlock the 170-hospital VA system, transitioning from a successful pilot to active system-wide expansion.Increased commercial infrastructure to 55 territ ...